TipRanks
Advertisement
Advertisement

KTTA Stock Latest News

Pasithea Therapeutics Announces Nasdaq Warrant Expiration
Company AnnouncementsPasithea Therapeutics Announces Nasdaq Warrant Expiration
1M ago
8K
KTTA
Pasithea Therapeutics Shareholders Approve Reverse Stock Split
PremiumCompany Announcements
Pasithea Therapeutics Shareholders Approve Reverse Stock Split
1M ago
8K
KTTA
Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance
PremiumCompany Announcements
Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance
2M ago
8K
KTTA
Pasithea Therapeutics announces updated data from PAS-004 trial
PremiumThe Fly
Pasithea Therapeutics announces updated data from PAS-004 trial
4M ago
KTTA
Pasithea Therapeutics announces amendments to PAS-004 clinical study
PremiumThe Fly
Pasithea Therapeutics announces amendments to PAS-004 clinical study
4M ago
KTTA
Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA
PremiumThe FlyPasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA
5M ago
KTTA
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
Premium
The Fly
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
5M ago
KTTA
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained
Premium
Ratings
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained
5M ago
KTTA
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
PremiumCompany Announcements
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
6M ago
8K
KTTA
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
PremiumThe Fly
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
6M ago
KTTA
Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004
PremiumThe Fly
Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004
6M ago
KTTA
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
PremiumCompany Announcements
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
8M ago
8K
KTTA
Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization
PremiumCompany AnnouncementsPasithea Therapeutics Shareholders Approve Expanded Equity Authorization
9M ago
8K
KTTA
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway
Premium
Ratings
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway
9M ago
KTTA
Pasithea Therapeutics provides updated timeline on PAS-004 programs
Premium
The Fly
Pasithea Therapeutics provides updated timeline on PAS-004 programs
9M ago
KTTA
Pasithea Therapeutics Regains Nasdaq Compliance
PremiumCompany Announcements
Pasithea Therapeutics Regains Nasdaq Compliance
10M ago
8K
KTTA
Pasithea Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Pasithea Therapeutics initiated with a Buy at H.C. Wainwright
11M ago
KTTA
3 Penny Stocks to Watch Now, 12/2/25
PremiumMarket News
3 Penny Stocks to Watch Now, 12/2/25
11M ago
ADTX
BEAM
Pasithea Therapeutics Completes $60M Public Offering
PremiumCompany Announcements
Pasithea Therapeutics Completes $60M Public Offering
11M ago
8K
KTTA
Pasithea Therapeutics prices 80M shares at 75c in public offering
PremiumThe FlyPasithea Therapeutics prices 80M shares at 75c in public offering
11M ago
KTTA
3 Penny Stocks to Watch Now, 11/27/25
Premium
Market News
3 Penny Stocks to Watch Now, 11/27/25
11M ago
AMBR
KTTA
Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004
Premium
Company Announcements
Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004
11M ago
8K
KTTA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >